Gw Pharma ADR (GWPH) 82.28 $GWPH GNC Holdings H
Post# of 273258
Posted On: 09/02/2016 9:01:16 AM
Gw Pharma ADR (GWPH) 82.28 $GWPH
GNC Holdings Hit by Dismal Q2 Results, Competition Rife
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 8:12AM CDT
GNC Holdings (GNC) ended second-quarter 2016 on a disappointing note as its revenue figure failed to meet the Zacks Consensus Estimate.
GWPH: 82.28 (+0.53), GNC: 20.81 (-0.22), QDEL: 21.74 (-0.03), LNTH: 9.95 (+0.45)
Medtronic Posts Positive Long-term Data for Micra Pacemaker
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 8:00AM CDT
Medtronic's (MDT) Micra TPS also successfully reduced the risk of patient hospitalization by 47% and risk of system revisions by 82%
MDT: 87.00 (+0.02), GWPH: 82.28 (+0.53), QDEL: 21.74 (-0.03), LNTH: 9.95 (+0.45)
Boston Scientific's Innovation & Emerging Market Raise Hope
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 7:08AM CDT
On Aug 31, 2016, we issued an updated research report on leading medical devices company, Boston Scientific Corporation (BSX).
BSX: 24.33 (+0.51), GWPH: 82.28 (+0.53), QDEL: 21.74 (-0.03), LNTH: 9.95 (+0.45)
NuVasive: Strong Q2 Results, Overseas Holds Solid Prospect
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 9:13AM CDT
NuVasive (NUVA) posted strong results in the second quarter of 2016, with both earnings and revenues squarely beating the Zacks Consensus Estimate
GWPH: 82.28 (+0.53), QDEL: 21.74 (-0.03), LNTH: 9.95 (+0.45), NUVA: 66.06 (+0.59)
Phibro Animal Health (PAHC) Q4 Earnings Top, Decline Y/Y
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 6:51AM CDT
Phibro's (PAHC) fiscal fourth-quarter bottom line comfortably exceeding the Zacks Consensus Estimate, while its revenues expanded in low-single-digit on a year-over-year basis.
GWPH: 82.28 (+0.53), PAHC: 25.59 (+1.32), QDEL: 21.74 (-0.03), NUVA: 66.06 (+0.59)
Medtronic on Track with Covidien Synergy, Buys HeartWare
Zacks Equity Research - Zacks Investment Research - Mon Aug 29, 9:02AM CDT
On Aug 26, 2016, we issued an updated research report on Medtronic plc (MDT).
MDT: 87.00 (+0.02), GWPH: 82.28 (+0.53), QDEL: 21.74 (-0.03), NUVA: 66.06 (+0.59)
Hill-Rom (HRC) Hits New 52-Week High on Solid Q3 Results
Zacks Equity Research - Zacks Investment Research - Mon Aug 29, 8:08AM CDT
Shares of Hill-Rom (HRC) rallied to a new 52-week high of $59.45 on Aug 26.
GWPH: 82.28 (+0.53), QDEL: 21.74 (-0.03), NUVA: 66.06 (+0.59), HRC: 59.75 (+0.50)
Medtronic (MDT) Beats Q1 Earnings, Revenues Closely In-Line
Zacks Equity Research - Zacks Investment Research - Thu Aug 25, 4:29PM CDT
Medtronic plc (MDT)'s reported financial results for first-quarter fiscal 2017. Adjusted earnings per share (EPS) in the reported quarter came in at $1.03, 2 cents ahead of the Zacks Consensus Estimate.
MDT: 87.00 (+0.02), GWPH: 82.28 (+0.53), QDEL: 21.74 (-0.03), NUVA: 66.06 (+0.59)
TG Therapeutics (TGTX) Catches Eye: Stock Jumps 9.2%
Zacks Equity Research - Zacks Investment Research - Thu Aug 25, 7:00AM CDT
TG Therapeutics, Inc. (TGTX) was a big mover last session, as the company saw its shares rise over 9% on the day.
GWPH: 82.28 (+0.53), TGTX: 6.51 (+0.16)
Will GW Pharmaceuticals (GWPH) Crush Estimates at Its Next Earnings Report?
Zacks Equity Research - Zacks Investment Research - Wed Aug 24, 8:00AM CDT
GW Pharmaceuticals has a favorable Zacks Rank and a positive Earnings ESP, which is a great sign of a coming earnings beat.
GWPH: 82.28 (+0.53)
Medtronic's HeartWare Takeover Complete for $1.1 Billion
Zacks Equity Research - Zacks Investment Research - Wed Aug 24, 4:54AM CDT
With HeartWare in its kitty, Medtronic (MDT) will now gracefully lead the global VAD market for heart failure patients.
MDT: 87.00 (+0.02), GWPH: 82.28 (+0.53), QDEL: 21.74 (-0.03), HTWR: 58.20 (+0.22), NUVA: 66.06 (+0.59)
Phibro Animal Health: Currency & Competition Woes Persist
Zacks Equity Research - Zacks Investment Research - Tue Aug 23, 3:33PM CDT
Phibro (PAHC) faces competition from generic alternatives of some of its products that may weigh on its future financial health and operational performance.
GWPH: 82.28 (+0.53), PAHC: 25.59 (+1.32), BAX: 46.18 (-0.55), QDEL: 21.74 (-0.03)
The Growth of the Legal and Medical Marijuana Markets
PR Newswire - Tue Aug 23, 8:57AM CDT
The legal marijuana market in the United States is projected to grow substantially in 2016. A recent report by New Frontier and ArcView Market Research projected the marijuana market in the United States to grow to $7.1 billion in 2016, which represents a 26% growth comparing to 2015. Veritas Pharma Inc. (OTC: VRTHF), Cara Therapeutics Inc (NASDAQ: CARA), Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE), Terra Tech Corp. (TRTC), GW Pharmaceuticals PLC (NASDAQ: GWPH)
CARA: 5.38 (-0.04), GWPH: 82.28 (+0.53), ZYNE: 8.57 (+0.09)
Illumina Rallies on Rumors of Takeover by Thermo Fisher
Zacks Equity Research - Zacks Investment Research - Tue Aug 23, 8:42AM CDT
Reportedly, Thermo Fisher (TMO) has made an all-stock offer of $30 billion to acquire Illumina (ILMN), which currently has a market cap of over $25 billion.
GWPH: 82.28 (+0.53), TMO: 150.95 (-1.24), QDEL: 21.74 (-0.03), ILMN: 168.56 (+0.22)
Cardiovascular Systems (CSII) Catches Eye: Stock Up 5.6%
Zacks Equity Research - Zacks Investment Research - Tue Aug 23, 7:40AM CDT
Cardiovascular Systems Inc. (CSII) saw its shares almost 6% in the last trading session.
CSII: 24.45 (-0.02), GWPH: 82.28 (+0.53)
Insys Therapeutics Starts Enrollment in Cannabidiol Trial
Zacks Equity Research - Zacks Investment Research - Fri Aug 19, 4:32PM CDT
Insys Therapeutics, Inc. (INSY) announced that it has enrolled the first patient in a phase II trial on its pharmaceutical cannabidiol (CBD) product candidate.
INSY: 14.36 (+0.09), GWPH: 82.28 (+0.53), CORT: 5.35 (+0.02), PCRX: 40.37 (+0.74)
Bruker's Q2 Results Disappoint, Product Launches Continue
Zacks Equity Research - Zacks Investment Research - Thu Aug 18, 7:14AM CDT
On Aug 12, we issued an updated research report on Billerica, MA-based Bruker Corporation (BRKR).
GWPH: 82.28 (+0.53), QDEL: 21.74 (-0.03), BRKR: 22.44 (+0.08), NUVA: 66.06 (+0.59)
Phibro (PAHC) Focuses on Growth Amid Pricing Pressure
Zacks Equity Research - Zacks Investment Research - Wed Aug 17, 9:30AM CDT
On Aug 16, 2016, we issued an updated research report on Phibro Animal Health Corporation (PAHC).
GWPH: 82.28 (+0.53), PAHC: 25.59 (+1.32), QDEL: 21.74 (-0.03), NUVA: 66.06 (+0.59)
Zimmer Biomet Acquires CD Diagnostics, Targets PJI Market
Zacks Equity Research - Zacks Investment Research - Wed Aug 17, 9:27AM CDT
Zimmer Biomet Holdings, Inc. (ZBH) announced the buyout of CD Diagnostics, an immunoassays and biomarker testing developer.
ZBH: 128.35 (-1.26), GWPH: 82.28 (+0.53), QDEL: 21.74 (-0.03), NUVA: 66.06 (+0.59)
GW Pharmaceuticals Enters Oversold Territory (GWPH)
MarketNewsVideo.com - Tue Aug 16, 12:38PM CDT
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative...
GWPH: 82.28 (+0.53)
GNC Holdings Hit by Dismal Q2 Results, Competition Rife
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 8:12AM CDT
GNC Holdings (GNC) ended second-quarter 2016 on a disappointing note as its revenue figure failed to meet the Zacks Consensus Estimate.
GWPH: 82.28 (+0.53), GNC: 20.81 (-0.22), QDEL: 21.74 (-0.03), LNTH: 9.95 (+0.45)
Medtronic Posts Positive Long-term Data for Micra Pacemaker
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 8:00AM CDT
Medtronic's (MDT) Micra TPS also successfully reduced the risk of patient hospitalization by 47% and risk of system revisions by 82%
MDT: 87.00 (+0.02), GWPH: 82.28 (+0.53), QDEL: 21.74 (-0.03), LNTH: 9.95 (+0.45)
Boston Scientific's Innovation & Emerging Market Raise Hope
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 7:08AM CDT
On Aug 31, 2016, we issued an updated research report on leading medical devices company, Boston Scientific Corporation (BSX).
BSX: 24.33 (+0.51), GWPH: 82.28 (+0.53), QDEL: 21.74 (-0.03), LNTH: 9.95 (+0.45)
NuVasive: Strong Q2 Results, Overseas Holds Solid Prospect
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 9:13AM CDT
NuVasive (NUVA) posted strong results in the second quarter of 2016, with both earnings and revenues squarely beating the Zacks Consensus Estimate
GWPH: 82.28 (+0.53), QDEL: 21.74 (-0.03), LNTH: 9.95 (+0.45), NUVA: 66.06 (+0.59)
Phibro Animal Health (PAHC) Q4 Earnings Top, Decline Y/Y
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 6:51AM CDT
Phibro's (PAHC) fiscal fourth-quarter bottom line comfortably exceeding the Zacks Consensus Estimate, while its revenues expanded in low-single-digit on a year-over-year basis.
GWPH: 82.28 (+0.53), PAHC: 25.59 (+1.32), QDEL: 21.74 (-0.03), NUVA: 66.06 (+0.59)
Medtronic on Track with Covidien Synergy, Buys HeartWare
Zacks Equity Research - Zacks Investment Research - Mon Aug 29, 9:02AM CDT
On Aug 26, 2016, we issued an updated research report on Medtronic plc (MDT).
MDT: 87.00 (+0.02), GWPH: 82.28 (+0.53), QDEL: 21.74 (-0.03), NUVA: 66.06 (+0.59)
Hill-Rom (HRC) Hits New 52-Week High on Solid Q3 Results
Zacks Equity Research - Zacks Investment Research - Mon Aug 29, 8:08AM CDT
Shares of Hill-Rom (HRC) rallied to a new 52-week high of $59.45 on Aug 26.
GWPH: 82.28 (+0.53), QDEL: 21.74 (-0.03), NUVA: 66.06 (+0.59), HRC: 59.75 (+0.50)
Medtronic (MDT) Beats Q1 Earnings, Revenues Closely In-Line
Zacks Equity Research - Zacks Investment Research - Thu Aug 25, 4:29PM CDT
Medtronic plc (MDT)'s reported financial results for first-quarter fiscal 2017. Adjusted earnings per share (EPS) in the reported quarter came in at $1.03, 2 cents ahead of the Zacks Consensus Estimate.
MDT: 87.00 (+0.02), GWPH: 82.28 (+0.53), QDEL: 21.74 (-0.03), NUVA: 66.06 (+0.59)
TG Therapeutics (TGTX) Catches Eye: Stock Jumps 9.2%
Zacks Equity Research - Zacks Investment Research - Thu Aug 25, 7:00AM CDT
TG Therapeutics, Inc. (TGTX) was a big mover last session, as the company saw its shares rise over 9% on the day.
GWPH: 82.28 (+0.53), TGTX: 6.51 (+0.16)
Will GW Pharmaceuticals (GWPH) Crush Estimates at Its Next Earnings Report?
Zacks Equity Research - Zacks Investment Research - Wed Aug 24, 8:00AM CDT
GW Pharmaceuticals has a favorable Zacks Rank and a positive Earnings ESP, which is a great sign of a coming earnings beat.
GWPH: 82.28 (+0.53)
Medtronic's HeartWare Takeover Complete for $1.1 Billion
Zacks Equity Research - Zacks Investment Research - Wed Aug 24, 4:54AM CDT
With HeartWare in its kitty, Medtronic (MDT) will now gracefully lead the global VAD market for heart failure patients.
MDT: 87.00 (+0.02), GWPH: 82.28 (+0.53), QDEL: 21.74 (-0.03), HTWR: 58.20 (+0.22), NUVA: 66.06 (+0.59)
Phibro Animal Health: Currency & Competition Woes Persist
Zacks Equity Research - Zacks Investment Research - Tue Aug 23, 3:33PM CDT
Phibro (PAHC) faces competition from generic alternatives of some of its products that may weigh on its future financial health and operational performance.
GWPH: 82.28 (+0.53), PAHC: 25.59 (+1.32), BAX: 46.18 (-0.55), QDEL: 21.74 (-0.03)
The Growth of the Legal and Medical Marijuana Markets
PR Newswire - Tue Aug 23, 8:57AM CDT
The legal marijuana market in the United States is projected to grow substantially in 2016. A recent report by New Frontier and ArcView Market Research projected the marijuana market in the United States to grow to $7.1 billion in 2016, which represents a 26% growth comparing to 2015. Veritas Pharma Inc. (OTC: VRTHF), Cara Therapeutics Inc (NASDAQ: CARA), Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE), Terra Tech Corp. (TRTC), GW Pharmaceuticals PLC (NASDAQ: GWPH)
CARA: 5.38 (-0.04), GWPH: 82.28 (+0.53), ZYNE: 8.57 (+0.09)
Illumina Rallies on Rumors of Takeover by Thermo Fisher
Zacks Equity Research - Zacks Investment Research - Tue Aug 23, 8:42AM CDT
Reportedly, Thermo Fisher (TMO) has made an all-stock offer of $30 billion to acquire Illumina (ILMN), which currently has a market cap of over $25 billion.
GWPH: 82.28 (+0.53), TMO: 150.95 (-1.24), QDEL: 21.74 (-0.03), ILMN: 168.56 (+0.22)
Cardiovascular Systems (CSII) Catches Eye: Stock Up 5.6%
Zacks Equity Research - Zacks Investment Research - Tue Aug 23, 7:40AM CDT
Cardiovascular Systems Inc. (CSII) saw its shares almost 6% in the last trading session.
CSII: 24.45 (-0.02), GWPH: 82.28 (+0.53)
Insys Therapeutics Starts Enrollment in Cannabidiol Trial
Zacks Equity Research - Zacks Investment Research - Fri Aug 19, 4:32PM CDT
Insys Therapeutics, Inc. (INSY) announced that it has enrolled the first patient in a phase II trial on its pharmaceutical cannabidiol (CBD) product candidate.
INSY: 14.36 (+0.09), GWPH: 82.28 (+0.53), CORT: 5.35 (+0.02), PCRX: 40.37 (+0.74)
Bruker's Q2 Results Disappoint, Product Launches Continue
Zacks Equity Research - Zacks Investment Research - Thu Aug 18, 7:14AM CDT
On Aug 12, we issued an updated research report on Billerica, MA-based Bruker Corporation (BRKR).
GWPH: 82.28 (+0.53), QDEL: 21.74 (-0.03), BRKR: 22.44 (+0.08), NUVA: 66.06 (+0.59)
Phibro (PAHC) Focuses on Growth Amid Pricing Pressure
Zacks Equity Research - Zacks Investment Research - Wed Aug 17, 9:30AM CDT
On Aug 16, 2016, we issued an updated research report on Phibro Animal Health Corporation (PAHC).
GWPH: 82.28 (+0.53), PAHC: 25.59 (+1.32), QDEL: 21.74 (-0.03), NUVA: 66.06 (+0.59)
Zimmer Biomet Acquires CD Diagnostics, Targets PJI Market
Zacks Equity Research - Zacks Investment Research - Wed Aug 17, 9:27AM CDT
Zimmer Biomet Holdings, Inc. (ZBH) announced the buyout of CD Diagnostics, an immunoassays and biomarker testing developer.
ZBH: 128.35 (-1.26), GWPH: 82.28 (+0.53), QDEL: 21.74 (-0.03), NUVA: 66.06 (+0.59)
GW Pharmaceuticals Enters Oversold Territory (GWPH)
MarketNewsVideo.com - Tue Aug 16, 12:38PM CDT
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative...
GWPH: 82.28 (+0.53)
(0)
(0)Scroll down for more posts ▼